Hana Safah, MD

Hana Safah, MD, and Corey Cutler, MD, MPH, conclude with clinical insights on addressing medication access and the supportive care needs of patients with GvHD.

Drs Cutler and Safah look to the future of chronic GvHD treatment and discuss ongoing research, highlighting studies investigating axatilimab and abatacept.

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

Drs Safah and Cutler discuss treatment practices for patients with steroid-refractory graft-vs-host disease and highlight patients who are steroid dependent.

Hematologist-oncologists discuss the first-line treatment options for patients with chronic GvHD and the advantages and disadvantages of steroids.

Hana Safah, MD, reviews the NIH staging system for graft-vs-host disease and discusses the importance of staging in determining prognosis and informing treatment decisions.

Corey Cutler, MD, MPH, discusses the role of prognostic markers in graft-vs-host disease and how they can potentially inform treatment selection.

Hematologist-oncologists Corey Cutler, MD, MPH, and Hana Safah, MD, discuss how graft-vs-host disease presents and the importance of early intervention.

Experts on graft-vs-host disease (GvHD) introduce themselves and provide an overview of GvHD, highlighting diagnosis, symptoms, risk stratification, and prevention.

The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.

The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.

Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.

Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.

Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.

Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.

Krina Patel, MD, reviews recent data from the MAJESTIC studies on immunotherapy combination treatments in R/R MM.

Amrita Krishnan, MD, details how she approaches retreating a patient with R/R MM with a BCMA-targeting bispecific agent.

Hana Safah, MD, and Noopur Raje, MD, discuss data on BCMA-targeting bispecifics teclistamab and elrantamab for treatment of relapsed/refractory multiple myeloma.

The panel discusses the strategies for reducing or preventing COVID infection in patients being treated for early relapse multiple myeloma with CD38 monoclonal antibodies.

Noopur Raje, MD, explains the treatment decision-making process for early relapse multiple myeloma.

Hana Safa, MD, shares data on quadruplet therapies in the treatment of relapsed multiple myeloma.

The panel debates the options for treatment of late relapsed multiple myeloma.

Drs Hana Safah and Krina Patel share data from key clinical trials investigating the treatment of relapsed multiple myeloma.

Dr Amrita Krishnan explains the difference between biochemical and clinical relapse in multiple myeloma.

Noopur Raje, MD, details the data on treatment duration in older patients with multiple myeloma and transplant-eligible patients.

Amrita Krishnan, MD, and Hana Safah, MD, discuss how to measure frailty in patient with multiple myeloma.

Hana Safah, MD, explains the common treatment approaches for patients with transplant-ineligible multiple myeloma.

Sagar Lonial, MD, introduces the expert panel and starts a conversation on data updates in the treatment of transplant-eligible multiple myeloma.